Literature DB >> 16119900

Facial paralysis caused by malignant skull base neoplasms.

Sam J Marzo1, John P Leonetti, Guy Petruzzelli.   

Abstract

OBJECT: Bell palsy remains the most common cause of facial paralysis. Unfortunately, this term is often erroneously applied to all cases of facial paralysis.
METHODS: The authors performed a retrospective review of data obtained in 11 patients who were treated at a university-based referral practice between July 1988 and September 2001 and who presented with acute facial nerve paralysis mimicking Bell palsy. All patients were subsequently found to harbor an occult skull base neoplasm. A delay in diagnosis was demonstrated in all cases. Seven patients died of their disease, and four patients are currently free of disease.
CONCLUSIONS: Although Bell palsy remains the most common cause of peripheral facial nerve paralysis, patients in whom neoplasms invade of the facial nerve may present with acute paralysis mimicking Bell palsy that fails to resolve. Delays in diagnosis and treatment in such cases may result in increased rates of mortality and morbidity.

Entities:  

Mesh:

Year:  2002        PMID: 16119900     DOI: 10.3171/foc.2002.12.5.3

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  3 in total

1.  Management of Bell palsy: clinical practice guideline.

Authors:  John R de Almeida; Gordon H Guyatt; Sachin Sud; Joanne Dorion; Michael D Hill; Michael R Kolber; Jane Lea; Sylvia Loong Reg; Balvinder K Somogyi; Brian D Westerberg; Chris White; Joseph M Chen
Journal:  CMAJ       Date:  2014-06-16       Impact factor: 8.262

2.  Facial paralysis for the plastic surgeon.

Authors:  Aaron M Kosins; Keith A Hurvitz; Gregory Rd Evans; Garrett A Wirth
Journal:  Can J Plast Surg       Date:  2007

3.  Not So Benign Bell's Palsy: Malignant Peripheral Nerve Sheath Tumor of the Facial Nerve Involving the Temporal Bone.

Authors:  Christopher N Nguyen; Niharika Mallepally; Jules R Tabilona; Lee B Lu
Journal:  J Gen Intern Med       Date:  2021-01-19       Impact factor: 5.128

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.